Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding

BACKGROUND: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation. Suitable dose of the drug for the patient is selected based on CHA2DS2-VASc score and HAS-BLED sc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaji, Anitta, Thomas, Doody, Saju, Midhuna, Abraham, Suja, Nayak, Ramdas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003582/
https://www.ncbi.nlm.nih.gov/pubmed/36909213
http://dx.doi.org/10.4103/picr.picr_171_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003582/
https://www.ncbi.nlm.nih.gov/pubmed/36909213
http://dx.doi.org/10.4103/picr.picr_171_21

Ejemplares similares